MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
Our Pipeline and Products
Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.
Our pipeline refers to drugs in development, including those in preclinical testing, clinical development, regulatory approval and lifecycle management.
The information in the table reflects Menarini's development pipeline and is not intended for promotional or marketing purposes. The safety and efficacy of the investigational compounds, or investigational uses of marketed products have not been established and marketing approval has yet to be granted by regulatory authorities.
ONCOLOGY
- Focus on compound
- Foucs on indication
Legenda
- ABSSSI: Acute Bacterial Skin and Skin Structure Infections
- ADC: Antibody Drug Conjugate
- CABP: Community Acquired Bacterial Pneumonia
- cIAI: Complicated Intra-Abdominal Infections
- cUTI: Complicated Urinary Tract Infections
- ER: Estrogen Receptor
- HABP: Hospital Acquired Bacterial Pneumonia
- IV: Intravenous
- PIM/FLT3i: PIM/FLT3 Kinase Inhibitor
- PI3Ki: Phosphatidylinositol 3-Kinase Inhibitor
- RETi: RET Kinase Inhibitor
- SME: Small Molecule Entity
- VABP: Ventilator Associated Bacterial Pneumonia
- XPO1i: XPO1 Inhibitor
- P: Preclinical
- I: Phase I
- II: Phase II
- III: Phase III
- F: Filing
- A: Approval
ANTI-INFECTIVES
- Focus on compound
- Foucs on indication
Legenda
- ABSSSI: Acute Bacterial Skin and Skin Structure Infections
- ADC: Antibody Drug Conjugate
- CABP: Community Acquired Bacterial Pneumonia
- cIAI: Complicated Intra-Abdominal Infections
- cUTI: Complicated Urinary Tract Infections
- ER: Estrogen Receptor
- HABP: Hospital Acquired Bacterial Pneumonia
- IV: Intravenous
- PIM/FLT3i: PIM/FLT3 Kinase Inhibitor
- PI3Ki: Phosphatidylinositol 3-Kinase Inhibitor
- RETi: RET Kinase Inhibitor
- SME: Small Molecule Entity
- VABP: Ventilator Associated Bacterial Pneumonia
- XPO1i: XPO1 Inhibitor
- P: Preclinical
- I: Phase I
- II: Phase II
- III: Phase III
- F: Filing
- A: Approval